Aurora effect is known as the aurora borealis or the northern lights. The former term was coined by Galileo in 1619, from the Roman goddess of the dawn and the Greek name for the north wind. The southern counterpart, the aurora australis or the southern lights, has features almost identical to the aurora borealis and changes simultaneously with changes in the northern auroral zone. The Aurora Australis is visible from high southern latitudes in Antarctica, Chile, Argentina, New Zealand, and Australia. A geomagnetic storm causes the auroral ovals (north and south) to expand, and bring the aurora to lower latitudes. The
Aurora inhibitor so named because the scattered mitotic spindles generated by mutant forms resemble the Aurora Borealis, have gained a great deal of attention as possible anticancer drug targets. The Aurora enzymes are particularly significant because they are involved in a direct path to the nucleosome by phosphorylating histone H3. Furthermore, Aurora kinases are known to be oncogenic and overexpressed in various forms of cancerous growth, including leukemia, colon cancer, prostate cancer and breast cancer tumors. So far three Aurora-kinase inhibitors have been described: ZM447439, Hesperadin and VX-680. The last is in advanced stages (Phase II clinical trial) of a joint drug